Canada markets open in 3 hours 32 minutes

OncoCyte Corporation (OCX)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
2.5100+0.0100 (+0.40%)
At close: 04:00PM EDT
2.5100 0.00 (0.00%)
After hours: 07:40PM EDT

OncoCyte Corporation

15 Cushing
Irvine, CA 92618
United States
949 409 7600
https://oncocyte.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full Time Employees: 43

Key Executives

NameTitlePayExercisedYear Born
Mr. Joshua RiggsPresident, CEO & Director373.2kN/A1983
Mr. James LiuSenior Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer192.48kN/A1996
Dr. Ekkehard Schutz M.D., Ph.D.Chief Science OfficerN/AN/AN/A
Mr. Peter HongVP, General Counsel & SecretaryN/AN/AN/A
Mr. Yuh-Min Chiang Ph.D.Senior Vice President of R&D and Product DevelopmentN/AN/AN/A
Ms. Sandra O'DonaldSenior Vice President of Business OperationsN/AN/AN/A
Dr. Michael D. West Ph.D.Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc.N/AN/A1953
Ms. Sara RiordanDirector of Medical EducationN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Corporate Governance

OncoCyte Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.